Neurocrine Biosciences Starts Phase 2 Trial of NBI-'567 for Alzheimer's Disease

By Public Technologies
  • Neurocrine Biosciences today launched a Phase 2 trial of NBI-'567 as an add-on treatment for cognitive impairment in mild to moderate Alzheimer's disease.
  • The study will enroll approximately 135 adults ages 50 to 85 receiving stable acetylcholinesterase inhibitor treatment.
  • Participants will receive a high or low once-daily oral dose, or placebo, over 12 weeks.
  • The trial will assess whether NBI-'567 improves cognitive performance, while evaluating safety and tolerability.
  • No results have been presented; the study is newly initiated.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurocrine Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610200830PR_NEWS_USPR_____LA76018) on October 20, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.